Date: 2012-06-19
Type of information: Production agreement
Compound: XD® high cell density process technology
Company: Royal DSM (The Netherlands) undisclosed major pharmaceutical company
Therapeutic area:
Type agreement: manufacturing
production
Action mechanism: XD® technology is a highly intensified cell culture process with titer achievement 5-to-15 times higher compared to current standard biomanufacturing processes. It is widely applicable for multiple products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.
Disease:
Details: DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM has signed a commercial agreement for contract manufacturing services using its proprietary XD® high cell density process technology with a major pharma company. DSM will complete the process development and commercial manufacturing for the products. These projects will be performed at the R&D and manufacturing site in Groningen and at new operations in Brisbane. The commercial demand will be met from Brisbane on a 500-litre XD® production line. Typically XD® has increased product titers by a factor of 5-to-15 times which means a 500L bioreactor can provide a DSM client with the same amount of drug substance as a 5000L stainless steel bioreactor at an overall lower cost.
Financial terms: Financial terms were not disclosed.
Latest news:
